Experimental vaccine partially protects monkeys from HIV-like infection

(Press-News.org) MEDIA AVAILABILITY Experimental vaccine partially protects monkeys from HIV-like Infection: Study reveals factors associated with prevention, control of HIV infection

WHAT: New vaccine research in monkeys suggests that scientists are homing in on the critical ingredients of a protective HIV vaccine and identifies new HIV vaccine candidates to test in human clinical trials. The research, which appears online in Nature on Jan. 4, was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

In the study, scientists report that several Simian Immunodeficiency Virus (SIV) prime-boost vaccine regimens have demonstrated partial protection against acquisition of infection by a virulent, tough-to-neutralize SIV strain that is different from the strain used to make the vaccine—a scenario analogous to what people might encounter if an HIV vaccine were available. The experimental vaccine regimens reduced the monkeys' likelihood of becoming infected per exposure to SIV by 80 to 83 percent compared to a placebo vaccine regimen. Further, in those monkeys that did become infected, the experimental vaccine regimens substantially reduced the amount of virus in the blood compared to controls. Now plans are underway for early-stage clinical trials of a human-adapted version of one of the study's prime-boost vaccine combinations.

The best predictor of protection from SIV in the vaccinated monkeys was the presence of antibodies that latched onto the virus surface protein. This finding reinforces what scientists have learned so far about why the first modestly effective HIV vaccine (http://www.niaid.nih.gov/news/newsreleases/2009/Pages/ThaiVaxStudy.aspx) worked in humans and indicates that the HIV surface protein Env is a critical vaccine ingredient. The new research also provides strong evidence that the immune system's mechanism for preventing infection is significantly different from its mechanism for controlling viral replication.

### The research was led by first author Dan Barouch, M.D., Ph.D., of Beth Israel Deaconess Medical Center at Harvard Medical School and the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard. The senior authors of the new paper are Nelson Michael, M.D., Ph.D., of the U.S. Military HIV Research Program (MHRP), and Jaap Goudsmit, M.D., Ph.D., of Crucell Holland BV. NIAID intramural investigators Vanessa Hirsch, S.D., D.V.M., and Ilnour Ourmanov, Ph.D., collaborated on the research. MHRP and the Ragon Institute co-funded the studies with NIAID.

ARTICLE: D Barouch et al., Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature DOI: 10.1038/nature10766 (2012).

WHO: NIAID Director Anthony S. Fauci, M.D., is available for interviews.

CONTACT: To schedule an interview, please contact Laura Sivitz Leifman, 301-402-1663, sivitzl@niaid.nih.gov.

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.

NIH...Turning Discovery Into Health